APE1/Ref-1 Regulates STAT3 Transcriptional Activity and APE1/Ref-1–STAT3 Dual-Targeting Effectively Inhibits Pancreatic Cancer Cell Survival

Angelo A. Cardoso, Yalin Jiang, Meihua Luo, April M. Reed, Safi Shahda, Ying He, Anirban Maitra, Mark R. Kelley, Melissa L. Fishel

Introduction

Pancreatic cancer is a largely incurable disease, with patients facing the worst 5-year survival rate of any cancer. The challenge is to identify molecular effectors that critically regulate the survival of pancreatic ductal adenocarcinoma (PDAC) cells, to devise effective molecular-targeted strategies that can prevent or minimize the selection of resistant tumor variants, and overcome the protective role of the tumor-associated fibrosis and stroma. Increasing evidence supports the need for strategies targeting multiple molecular mediators of critical functions of pancreatic ductal adenocarcinoma cells. Intracellular redox state modulates the activity of various signal transduction pathways and biological processes, including cell survival, drug resistance and responsiveness to microenvironmental factors. Recently, it has been shown that the transcription factor STAT3 is under redox control, but the mechanisms involved in its regulation are unknown. Here, we demonstrate for the first time that STAT3 DNA binding and transcriptional activity is directly regulated by the redox function of the APE1/Ref-1 endonuclease, using overexpression and redox-specific mutational strategies, and gene knockdown. Also, pharmacological blockade of APE1/Ref-1 by the redox-selective inhibitor E3330 abrogates STAT3 DNA binding. Since APE1/Ref-1 also exerts redox control on other cancer-associated transcription factors, we assessed the impact of dual-targeting of STAT3 signaling and APE1/Ref-1 redox on pancreatic cancer cell functions. We observed that disruption of APE1/Ref-1 redox activity synergizes with STAT3 blockade to potently inhibit the proliferation and viability of human PDAC cells. Mechanistically, we show that STAT3–APE1/Ref-1 dual targeting promotes marked tumor cell apoptosis, with engagement of caspase-3 signaling, which are significantly increased in comparison to the effects triggered by single target blockade. Also, we show that STAT3–APE1/Ref-1 dual blockade results in significant inhibition of tumor cell migration. Overall, this work demonstrates that the transcriptional activity of STAT3 is directly regulated by the redox function of APE1/Ref-1, and that concurrent blockade of STAT3 and APE1/Ref-1 redox synergize effectively inhibit critical PDAC cell functions.
established APE1 as a potential molecular target in PDAC, by demonstrating that human adenocarcinoma and peri-pancreatic metastases exhibit increased APE1 expression [11], and that blockade of APE1 redox activity delays tumor progression in xenograft models of human PDAC, including patient-derived tumor cells [4].

STAT3 is a transcription factor that regulates critical cell functions and plays important roles in several cancers [12–15]. STAT3 signaling has been implicated in pancreatic cancer biology, namely by mediating or regulating cell survival, tumor angiogenesis and metastasis [16–18]. Although STAT3 signaling can be engaged and modulated by different processes, the impact of oxidative stress and its redox status are largely unknown. A recent report demonstrated that STAT3 activity is under redox control and identified the critical oxidation-sensitive cysteines in the STAT3 DNA binding domain [19,20]. However, the modifier of STAT3 which converts it from an oxidized into a reduced form has not been identified. APE1 physically interacts with STAT3 on the VEGF promoter [21] and enhances IL-6-induced DNA binding activity of STAT3 in HepG2 cells [22]. However, it is unknown whether APE1 is involved in the redox control of STAT3 activity, and whether the cellular redox status affects STAT3 signaling in PDAC cells.

Here, we demonstrate that APE1 redox activity regulates STAT3 DNA binding and transcriptional activity, using gene silencing, overexpression of WT or redox-defective APE1, and redox-selective pharmacological inhibition. Blockade of APE1 redox synergizes with STAT3 selective antagonists to markedly inhibit the proliferation and survival of human PDAC cells, promoting cell apoptosis. These studies identify the mechanism by which APE1 regulates STAT3 activity, and establishes the rationale for the development of APE1–STAT3 dual-targeting strategies for the treatment of PDAC.

Results

Redox Control of STAT3 Activity in PDAC Cells

Although STAT3 DNA binding is reportedly under redox control [20], the molecular mechanism mediating this regulation is unknown. Here, we investigated whether APE1 regulates the DNA binding and transcriptional activities of STAT3 in PDAC. We confirmed activation of STAT3 signaling using immunoblotting and EMSA (Figure 1A, B). Both patient-derived and immortalized cell lines express APE1 and exhibit STAT3 phosphorylation (residue Y705) and DNA binding; as expected, STAT3 DNA binding is enhanced following stimulation with IL-6. To confirm the specificity of STAT3 DNA binding, we performed EMSA competition assays using cold DNA probes (WT or mutant, STAT3-binding-defective sequences). As shown in Figure 1C, a dose-dependent decrease in STAT3 DNA binding was observed using the WT competitor probe which wasn’t observed using the mutant probe. Specificity of this interaction was also demonstrated by a supershift band observed using a STAT3-specific antibody (Figure 1D).

We investigated the effects of oxidizing and reducing conditions on STAT3 binding to DNA as well as its putative regulation by APE1, using PDAC nuclear extracts and treatment with diamide or DTT. Oxidizing conditions (diamide) abrogate the binding of STAT3 to DNA (Figure 1E, F); in contrast, nuclear extracts treated with the reducing agent DTT showed enhanced STAT3 DNA binding in a dose-dependent manner (Figure 1E; 1.4 to 2-fold increase). Since the redox status of STAT3 affects its DNA binding activity, we then evaluated whether the redox function of APE1 modulates its DNA binding. Addition of reduced APE1 protein to PaCa-2 nuclear extracts increased STAT3 DNA binding 1.8-fold (Figure 1G). As controls, we demonstrated that unreduced APE1 and carry-over DTT from the reduction of APE1 (0.04 mM) do not stimulates STAT3 DNA binding. These studies indicate that STAT3 signaling is activated in PDAC, and that STAT3 binding to DNA is redox sensitive and is regulated by APE1.

STAT3 Transcriptional Activity is Increased by APE1 Overexpression and is Inhibited by APE1 Knockdown

Due to the multifunctional nature of APE1 with both DNA repair and redox activities, we performed experiments to further demonstrate that APE1 and its redox function is required for STAT3 DNA binding and activity. Using lentiviral transpositional reporter vector, pGreenFire-STAT3-Luc (pGF-STAT3-Luc) and pGreenFire-mCMV (negative control), from System Biosciences Inc. (Mountainview, CA), we generated stably expressing reporter cell lines to assay for STAT3 activity, similar to constructs used in previous studies with NF-kB, AP-1, and HIF-1 [4]. Panc-1 cells were transduced with pGF-STAT3-Luc, and single colonies were screened for basal STAT3 and IL-6-stimulated STAT3 activity. PDAC cells expressing STAT3-driven luciferase were transfected to transiently overexpress wtAPE1 or the redox-defective mutant C65A-APE1 (C65A). Overexpression of wtAPE1 stimulates the activity of STAT3 in both clones (~3-fold), an effect that was not seen in cells expressing the redox-dead APE1 mutant (Figure 2A). In overexpression experiments in Figure 2A, single colonies were assayed for luciferase activity after transient transfection with pcDNA, pcDNA-wt-APE1, and pcDNA-C65A-APE1, and normalization was done using Renilla as a transfection control.

Knockdown of APE1 does not Affect Total STAT3 Protein Levels, the STAT3 Phosphorylation or Nuclear Translocation

We then assessed the impact of APE1 knockdown on STAT3 activity in PDAC cells. As above, single colonies of pGF-STAT3-Luc were transiently transfected with APE1 siRNA for the experiments shown in Figure 2B. Results from pGF-STAT3-Luc clones #3 and #9 were pooled in experiments shown in Figure 2B with representative experiments for each clone shown in Figure S1A, B. Basal levels of STAT3 activity are significantly diminished when APE1 expression is knocked down using transient, specific siRNA (Figure 2B; p<0.001). The decrease in STAT3 activity by APE1 knockdown was more pronounced in cells stimulated with IL-6, further supporting a regulatory role for APE1 in the DNA binding activity of STAT3 (Figure 2B, p<0.05, and Figures S1A, B). The effects on STAT3 transcriptional activity when APE1 levels are decreased are not due to an increase in total STAT3 protein as shown by immunoblotting for total STAT3 protein (Figure 2C and quantitation of blots in Figure S1C) and by qPCR for STAT3 mRNA (Figure S1D). We also performed studies to show that the impact of APE1 on STAT3 signaling was restricted to the regulation of its DNA binding activity, and did not affect levels of STAT3 phosphorylation (Figure 2D and quantitation in Figure S1E). Furthermore, stimulation with IL-6 under conditions of APE1 knockdown did not affect total STAT3 protein levels (Figure 2E). As expected, stimulation with IL-6 increases the levels of p-STAT3, and this regulation of STAT3 activity is not dependent upon APE1 protein levels.

Next, we investigated the nuclear translocation of STAT3 by probing lysates from nuclei and cytoplasm of PaCa-2 cells transfected with APE1 siRNA or SC control; total STAT3 and phospho-STAT3 (Y705) were analyzed, with tubulin and Lamin B...
used as cytoplasmic and nuclear controls, respectively. As expected, stimulation with IL-6 resulted in marked increase in the levels of p-STAT3 (Fig. 2E, F). Normalization of p-STAT3 to Lamin B levels showed that there were no significant differences in nuclear p-STAT3 in the APE1-silenced versus SC control (0.83 fold change). This finding was confirmed both in whole cell extracts (Figure 2 D, E) and in nuclear extracts (Figure 2F). These observations further indicate that APE1 regulates STAT3 DNA binding without affecting other mechanisms of regulation, i.e. phosphorylation, nuclear translocation, or amount of total STAT3 protein under basal or IL-6-induced conditions.

APE1 Redox Inhibitor, E3330 Inhibits STAT3 Transcriptional Activity

To more specifically address the role of the redox function of APE1 on STAT3 transcriptional activity, we performed experiments using the small molecule E3330, which selectively inhibits APE1 redox activity without affecting its endonuclease function. [3,5] E3330 markedly inhibits STAT3 activity both in stable lines (Figure 3A; Figures S2A,B) as well as in transient luciferase assays (Figure S2C). Basal STAT3 activity was significantly inhibited by E3330 (Figure 3A; p<0.05) in a dose-dependent manner. Also, E3330 treatment significantly inhibited the STAT3 activity induced by IL-6 stimulation of PDAC cells (Figure 3A; p<0.05), which was abrogated at higher E3330 doses. This inhibition of STAT3 activity was not due to a decrease in total STAT3 protein levels or a reduction in p-STAT3 levels. Results from immunoblotting of whole cell lysates demonstrated that the amount of STAT3 protein and phosphorylated STAT3 protein (0.95-fold compared to DMSO control) after treatment with APE1 redox inhibitor, E3330 in PaCa-2 cells was not significantly changed (Figure 3B).

To further confirm the inhibition of STAT3 DNA binding by APE1 redox blockade, nuclear extracts from PaCa-2 cells were treated with E3330 and analyzed by EMSA for STAT3 binding; a dose-dependent decrease in STAT3 binding was observed (Figure 3C), with an IC50 for E3330 around 30 μM (Figure 3D). We also treated PaCa-2 cells with E3330 and then stimulated STAT3 DNA binding with IL-6 and assayed for STAT3 DNA binding using EMSA assay. As shown in Figure 3E and F, IL-6-induced STAT3 activity is inhibited dramatically following E3330 treatment in cells. Further supporting a decrease in STAT3 DNA
binding following inhibition of APE1 redox activity, expression of STAT3 target gene, Survivin is decreased in a dose-dependent manner both in patient-derived cells (Figure 3G) and in PaCa-2 cells (Figure S2D). These studies demonstrate that manipulation of APE1 expression and disruption of its redox function markedly affects STAT3 DNA binding and transcriptional activity.

Pharmacologic Blockade of APE1 and STAT3 Results in Synergistic Effects on Human PDAC Cells

First we show that treatment with two previously described STAT3 antagonists, STATTIC [23] and S3I-201 [24] inhibited phosphorylation of STAT3 (Figure 4 A,B) as well as cellular proliferation in PDAC cells (Figure 4C). Statistically significant inhibition of phosphorylation of Y705 is observed at doses of S3I-201 greater than 100 μM and with doses of STATTIC greater than 3.125 μM, as assessed by densitometry (p<0.05). At the inhibitory doses tested, these compounds did not affect the phosphorylation levels of STAT1 (Y701) or STAT5 (Y694) in these cells (Figure 4A,B). Functional studies using the MTS assay showed that STAT3 blockade markedly inhibits proliferation of both PDAC lines (Figure 4C), with ED_{50} of ~2.5 μM for PaCa-2 and ~4 μM for Panc-1 for STATTIC, and ED_{50} ~190 μM for STATTIC, and ED_{50} ~190 μM for STATTIC.
PaCa-2 and ~310 μM for Panc-1 for S3I-201. For both drugs, a strong association was observed between decrease in STAT3 phosphorylation and inhibition of proliferation of PDAC cells.

In addition to regulating the transcriptional activity of STAT3, APE1 also exerts redox control of other transcription factors, which have been implicated in pancreatic cancer (such as HIF-1α and NF-κB). [4,16,25] We then evaluated whether the combined blockade of STAT3 and APE1 redox activity synergize to more effectively inhibit human PDAC cells. Cell survival was assessed using the xCELLigence system, which monitors real-time changes in cell adherence, morphology and viability; [4,26] cell index (CI) was monitored over 72 h drug treatment. E3330 was used at doses that effectively inhibit APE1 redox activity, and STAT3 inhibitors at doses that were utilized in the MTS-based assay for cytotoxicity (Figure 4C) and that inhibited STAT3 phosphorylation in PDAC cells (Figure 4A,B and Ref. [24]). As single agents, minimal inhibition of PDAC cells was observed with E3330 or at the doses of STATTIC or S3I-201 used (Figure 4D,E). We observed that APE1 redox inhibition by E3330 synergizes with STAT3 blockade by STATTIC or S3I-201, resulting in potent inhibition of Panc-1 and PaCa-2 cells, but also of the primary Pa03C and Panc10.05 cells (Figure 4D,E). The potentiation of the inhibitory effects seen with this dual targeting, at sub-optimal doses of these agents, was observed both using xCELLigence (Figure 4) and MTS assays (Figure S3). Interestingly, in the patient-derived cells Pa03C and Panc10.05, this enhancement was observed at lower doses of E3330 than those observed with the established cell lines (data not shown). Blockade of signaling through both APE1 redox activity and STAT3 has dramatic effects on cell survival. To demonstrate that this effect was not due to a general redox phenomenon, we also combined STAT3 inhibitors with thioredoxin inhibitor, PX-12 [27–29]. Addition of STAT3 inhibitor S3I-201 to PX-12 treatment did not significantly enhance the effects of PX-12 (Table S1; assessed by comparison of ED25, ED50, and ED75).

Figure 3. STAT3 activity following treatment of PDAC cells with APE1 redox inhibitor, E3330. A) STAT3 reporter assay in Panc-1 cells following treatment with E3330 (24 h) and stimulation with IL-6 (6 h). Doses were based on survival data from previously published data [4]. * p<0.05 t test, n = 6 comparing DMSO control to drug-treated samples. B) Representative Western blot of PaCa-2 cells treated with E3330 (50 μM, 24 hr). C) Addition of E3330 to the EMSA reaction inhibits the STAT3 DNA binding of nuclear extracts stimulated with IL-6. Representative EMSA blot shown with quantitation of three independent experiments in D. * p<0.05, ** p<0.01, compared to DMSO control, using Student’s t test. E) STAT3 DNA binding via EMSA assay following treatment of PaCa-2 cells with E3330 (2 h) and then stimulated with IL-6 (50 ng/mL, 2 h) with quantitation in (F) where intensity of binding was compared to amount of STAT3 DNA binding with IL-6 stimulation; G) qPCR analysis of Survivin expression following E3330 treatment for 24 h in patient-derived cells, Pa02C. Shown is data from 2–3 individual experiments (avg±SE). Samples were run in triplicate and normalized to DMSO vehicle control.
doi:10.1371/journal.pone.0047462.g003

PaCa-2 and ~310 μM for Panc-1 for S3I-201. For both drugs, a strong association was observed between decrease in STAT3 phosphorylation and inhibition of proliferation of PDAC cells.

In addition to regulating the transcriptional activity of STAT3, APE1 also exerts redox control of other transcription factors, which have been implicated in pancreatic cancer (such as HIF-1α and NF-κB). [4,16,25] We then evaluated whether the combined blockade of STAT3 and APE1 redox activity synergize to more effectively inhibit human PDAC cells. Cell survival was assessed using the xCELLigence system, which monitors real-time changes in cell adherence, morphology and viability; [4,26] cell index (CI) was monitored over 72 h drug treatment. E3330 was used at doses that effectively inhibit APE1 redox activity, and STAT3 inhibitors at doses that were utilized in the MTS-based assay for cytotoxicity (Figure 4C) and that inhibited STAT3 phosphorylation in PDAC cells (Figure 4A,B and Ref. [24]). As single agents, minimal inhibition of PDAC cells was observed with E3330 or at the doses of STATTIC or S3I-201 used (Figure 4D,E). We observed that APE1 redox inhibition by E3330 synergizes with STAT3 blockade by STATTIC or S3I-201, resulting in potent inhibition of Panc-1 and PaCa-2 cells, but also of the primary Pa03C and Panc10.05 cells (Figure 4D,E). The potentiation of the inhibitory effects seen with this dual targeting, at sub-optimal doses of these agents, was observed both using xCELLigence (Figure 4) and MTS assays (Figure S3). Interestingly, in the patient-derived cells Pa03C and Panc10.05, this enhancement was observed at lower doses of E3330 than those observed with the established cell lines (data not shown). Blockade of signaling through both APE1 redox activity and STAT3 has dramatic effects on cell survival. To demonstrate that this effect was not due to a general redox phenomenon, we also combined STAT3 inhibitors with thioredoxin inhibitor, PX-12 [27–29]. Addition of STAT3 inhibitor S3I-201 to PX-12 treatment did not significantly enhance the effects of PX-12 (Table S1; assessed by comparison of ED25, ED50, and ED75).
To quantify potential drug synergisms, the Chou-Talalay method was used with increasing dose combinations of one STAT3 antagonist plus the APE1 inhibitor E3330. The ED50 for the three compounds was determined as shown above, using MTS assays (Figure 4 and Ref. [4]). Panc-1 or PaCa-2 cells were treated with two-drug combinations at fixed ratio of doses corresponding to 0.125, 0.25, 0.5, 0.75, 1, 1.125, and 1.25-fold of their individual ED50 values. As shown in Figure 4F, potent synergisms were observed with combination index values significantly <0.1, very strong synergy; 0.1–0.3: strong synergy; and 0.3–0.7: synergy.

Dual Targeting of APE1 Redox Activity and STAT3 Triggers Increase Apoptotic Effects in PDAC Cells

Subsequently, we performed mechanistic studies to examine whether these synergistic effects involve increased apoptotic cell death and engagement of the Caspase pathway. First, we used the Annexin-PE/7-AAD assay to assess cell death and viability in PDAC cells treated with the drug combinations indicated (Figure 5A,C). Panels A and B depict representative plots of the flow cytometry analyses, and show that the combination of E3330 with a STAT3 inhibitor markedly increase the frequency of Annexin-positive, non-viable cells; comparable results were seen for patient-derived cells (Figure 5B, D). Analyses of data from 4 to 6 individual experiments demonstrate that the combination of E3330 with STATTIC or with S3I-201 significantly increases pancreatic cancer cell death (Figure 5B). Furthermore, similar results are observed in the patient-derived cells in which a ~6-8-fold increase in cell death is observed with the combined targeting of APE1 and STAT3 (Figure 5B,D).

To evaluate the potential involvement of caspase-dependent cell death, we performed experiments measuring the activation of caspase 3 in PDAC cells treated with the same drug combinations, using a FITC-conjugated caspase-3 inhibitor (FITC-DEVD-FMK) and flow cytometry. As shown in Figure 6, although single agents did not induce marked caspase 3 activation, the combinatory effects of APE1 redox inhibition and STAT3 signaling synergize to markedly impair the survival of human pancreatic cancer cells, even at sub-optimal doses of the individual agents.
E3330 was combined with STAT3 (A, p<0.05) or with S3I-201 (B, p<0.05). Overall, these results show that by combining suboptimal doses of individual selective agents, the simultaneous targeting of APE1 redox and STAT3 signaling results in significant cell death of PDAC cells, with the engagement of caspase 3 proapoptotic effects.

**Dual Targeting of APE1 Redox and STAT3 Signaling Significantly Inhibits the Migration of PDAC Cells**

Finally, since cell migration represents an important step in the progression and dissemination of pancreatic cancer, we evaluated the effects of APE1 and STAT3 blockade on the response of PDAC cells to chemotactic stimuli, using the xCELLigence system. Serum-deprived Panc-1 cells were placed in upper chamber of a CIM plate, and stimulated with media supplemented with serum, which provides chemotactic stimuli (lower chamber). As expected, serum-starved Panc-1 cells do not migrate in the absence of chemotactic stimuli, and fibronectin coating helps the attachment of migrating cells (Figure S4A). Treatment of Panc-1 cells with E3330, STAT3 or S3I-201 as single agents resulted in limited inhibition of Panc-1 cell migration, even at relatively high doses of these compounds (Figure 7). However, combination of E3330 with S3I-201 (50 μM and 100 μM, Fig. S4D) or with STAT3TIC resulted in markedly decreased cell migration (Figure 7D,E), with both S3I-201/E3330 and STAT3TIC/E3330 combinations resulting in significant inhibitory effects in Panc-1 cell migration (Figure 7F, Figures S4D, p<0.01; Figure S6G, p<0.05 in comparison to E3330 alone and p<0.01 in comparison to STAT3TIC alone). Importantly, these drugs or combinations showed no significant effects on the viability of Panc-1 cells at the timepoints and doses assessed in the migration assays (Figure S4B,C). These results indicate that concurrent blockade of APE1 redox and STAT3 signaling cooperates also to inhibit the migration properties of PDAC cells.

**Discussion**

In this report, we demonstrate for the first time that STAT3 DNA binding is under redox control, which is mediated by the redox activity of APE1. Previous studies demonstrated that oxidation of critical cysteines residues in STAT3 protein through peroxide treatment could decrease STAT3 (but not STAT1) DNA binding and transcriptional activity [20]. Using nuclear extracts from PDAC cells, we systematically characterized the effects of
reducing and oxidizing conditions on STAT3 DNA binding. Clearly, STAT3 binds to DNA more effectively when reduced, and the redox activity of APE1 is capable of stimulating STAT3 DNA binding. Furthermore, manipulation of APE1 levels affects the DNA binding activity of STAT3. The concurrent blockade of STAT3 and APE1 redox activity acts synergistically to disrupt PDAC cell viability as well as their migration properties.

This is the first demonstration also that APE1 regulates the STAT3 DNA binding and transcriptional activity in PDAC cells. This finding points to the interaction of APE1 and STAT3 as part of the survival signaling in PDAC rather than a non-specific effect of general redox regulators. Overexpression of a redox-deficient APE1 protein failed to promote STAT3 transactivation in PDAC cells, and blockade of the redox function of APE1 via E3330 dramatically inhibited the transcriptional activity of STAT3, both basal levels as well as IL-6-induced activity. However, knockdown of APE1 decreases STAT3 activity without affecting its phosphorylation or nuclear translocation. Taken together, these data support the hypothesis that APE1 directly controls the DNA binding activity of STAT3. With the high levels of APE1 expression in PDAC tumors (Figure 1A, Ref. [11]), stimulation of STAT3 signaling through APE1’s redox activity may contribute to the threshold of STAT3 activity in the tumor leading to a more aggressive phenotype. Increase in STAT3 signal fitness through oncogenic events and/or tumor-associated extrinsic signals such as IL-6 may be partially driven through APE1.

Within the STAT family of transcription factors, STAT3 is the first STAT member to be shown to be regulated by APE1. Work by Li et al elegantly demonstrated using chimera STAT1/STAT3 proteins that STAT3, but not STAT1, is under redox control. [20] ROS can activate STAT signaling and anti-oxidants can inhibit this activation. [30] We have previously shown that knocking down of APE1 in PDAC cells does not increase ROS levels [11], and therefore its effects on STAT3 DNA-binding activity here

Figure 6. Dual STAT3– APE1 targeting activates Caspase 3 in PDAC cells. Panc-1 and PaCa-2 cells were treated with E3330 (50, 75 μM) and increasing amounts of STAT3 (A) or S3I-201 (B) and assayed for caspase 3 activity. The graphs represent >3 independent experiments; *, p<0.05, all compared to STAT3 inhibitor alone at corresponding dose.

doi:10.1371/journal.pone.0047462.g006
reported cannot be attributed to changes in ROS activity. An understanding of whether other STAT family members are regulated by APE1 is important due to their diverse roles in cellular function including cytokine and growth factor signaling, differentiation, inflammation, and senescence [31–33], and are part of ongoing studies. 

An exciting finding in this study is the dramatic synergy seen between APE1 and STAT3 blockade in patient-derived pancreatic cancer cells. Our study demonstrates the importance of APE1 redox function in regulating STAT3 DNA binding and transcriptional activity (Figure 6). However, APE1 does not regulate only the DNA binding of STAT3, but also controls the activity of NF-κB, AP-1, and HIF-1α [1,4]. STAT3, NF-κB, and HIF-1 signaling contribute to the crosstalk between the tumor and the tumor microenvironment (TME) [14,34–36]. APE1 also plays an important role in signaling within the TME through the regulation of these transcription factors. Therefore, using inhibitors that target two critical proteins, APE1 and STAT3, we can potentially disable multiple key pathways in PDAC cell survival, and to disrupt the integration of signals between tumor and the microenvironment [37]. This is particularly important in PDAC as the disease frequently presents with metastatic disease. Our approach is consistent with the idea of synthetic lethality in which the pairing of two hits is sufficient to more effectively trigger cancer cell death, markedly improving the efficacy of single-target agents [38]. Both of these proteins are upregulated in cancer and contribute to the resistance of the disease, leaving cancer cells “addicted” to their effector functions. Dual targeting of STAT3 and APE1 is not only efficacious in PDAC; we also observed significant synergy in glioblastoma cells (Fishel, Kelley, manuscript in preparation).
This is especially relevant in brain tumors, where STAT3 is important in the mesenchymal transformation [39]. As next steps, we will evaluate STAT3 and APE1 as molecular targets in xenograft models of human pancreatic cancer. A STAT3-selective inhibitor is now in a Phase I clinical trial for solid tumors and preclinical work with E3330 demonstrates its efficacy against patient-derived PDAC xenografts [4]. These studies will set the framework for a future clinical study using this dual-targeting STAT3–APE1 strategy.

The current standard of care for pancreatic cancer (debulking surgery coupled with chemotherapy and/or radiation) is largely palliative rather than curative, with rare cases of long-term regression. The effective targeting of PDAC cells remains a major clinical challenge. Monotherapies are largely ineffective, therefore one approach would be to develop two- or multi-hit approaches [38] targeting signaling pathways that critically regulate PDAC survival. Strategies, such as the one described here, involving synthetic lethality, the targeting of critical transcriptional programs, and molecular effectors of the crosstalk between the tumor and TME, may offer the most promise for clinical utility against this dreaded disease. Studies in animal models of PDAC confirm that dual- or multi-targeting approaches can increase anti-tumor responses [40,41]. APE1 and STAT3 are upregulated and play important roles in cancer, suggesting that tumor cells may be ‘addicted’ to their effector functions. In addition to biochemical and molecular data linking APE1 and STAT3 in PDAC cells, our studies reveal potent anti-tumor synergism of the combination of APE1 redox inhibition and STAT3 blockade. Therefore, we believe that targeting of the APE1–STAT3 molecular axis has great clinical potential as a novel approach to impair multiple PDAC cell survival mechanisms.

**Materials and Methods**

**Cell Lines and Patient-derived PDAC Cells**

Panc-1 and PaCa-2 were purchased from and authenticated by ATCC (Manassas, VA). Pa03C, Panc10.05, and Pa02C were obtained from Dr. Anirban Maitra at The Johns Hopkins University. [42] All cells were maintained at 37°C in 5% CO2 and grown in DMEM (Invitrogen; Carlsbad, CA) with 10% Serum (Hyclone; Logan, UT).

**Inhibitors**

E3330 was synthesized as previously described [3,43], and STAT3 selective inhibitors S3I-201 [24] and STATTIC [23] were purchased from Calbiochem.

**qRT-PCR Reactions**

qRT-PCR was used to measure the mRNA expression levels of STAT3 and STAT3 downstream target, survivin gene. PaCa-2 and patient-derived lines were treated with increasing amounts of E3330 for 24-h in media containing 1–2% serum, and total RNA was extracted from cells using the Qiagen RNeasy Mini kit (Valencia, CA) according to the manufacturer’s instructions. The extracted RNA was quantified by a Qubit fluorometer (Invitrogen Corp, Carlsbad, CA). First-strand cDNA was obtained from RNA using random hexamers and MultiScribe reverse transcriptase (Applied Biosystems, Foster City, CA). Quantitative PCR was

---

**Figure 8. Model showing inhibition of STAT3 phosphorylation and nuclear translocation via S3I-201 or STATTIC as well as inhibition of STAT3 DNA binding via APE1 disruption. TF = Transcription factor.**

doi:10.1371/journal.pone.0047462.g008
performed using Taqman Gene Expression assays and Universal PCR master mix (Applied Biosystems) in a 7900HT Sequence detection system (Applied Biosystems). The relative quantitative mRNA level was determined using the comparative Ct method using Actin (PaCa-2) or ribosomal protein large, P0 (RPLP0, patient lines) as the reference gene. [4] The primers for STAT3, survivin, Actin, and RPLP0 are commercially available (Applied Biosystems). Experiments were performed in triplicate for each sample.

Survival, Proliferation, and Synergy Studies
The proliferative capacity of PDAC cells was assessed using the xCELLigence system (Roche Applied Science, Indianapolis IN) [4,26] as well as MTS assay as previously described [4]. Combination Index Calculations. PDAC cells were seeded into 96-well plates as described previously, and ED_{50} of E3330, S3I-201, or STATTIC on growth were determined using the MTS assay. Drug interaction was evaluated using CalcuSyn software (Biosoft, Ferguson, MO), which is based on the Chou-Talalay method [44].

Transfection of PDAC Cells with APE1 and Scrambled siRNA
All siRNA transfections were performed as previously described [10,43,45,46]. STAT3 luciferase assays were conducted on day 3 following knockdown [11].

Western Blot Analysis
For whole cell lysates, cells were harvested, lysed in RIPA buffer (Santa Cruz Biotechnology; Santa Cruz, CA), and protein was quantified and electrophoresed. Nuclear and cytoplasmic extracts were isolated as in [47]. Immunoblotting was performed using the following antibodies: APE1 (Novus Biologicals; Littleton, CO), STAT1, STAT3, STAT5, p-STAT1(Y701), p-STAT3(Y705), p-STAT5 (Y694) (Cell Signaling; Danvers, MA), and tubulin (Sigma Aldrich) or GAPDH (Santa Cruz Biotechnology, Inc, Santa Cruz, CA) and protein was blotted overnight, followed by incubation with the respective antibody. Immunoblots were developed using SuperSignal West Pico chemiluminescent substrate (Pierce, Rockford, IL).

Electrophoretic Mobility Shift Assay (EMSA)
EMSA were performed as previously described [48] with the following modifications. For super-shift assay, 6 μg ST3 antibody (Santa Cruz Biotechnology, Inc, Santa Cruz, CA) was pre-incubated with 15 μg nuclear extract from PaCa-2 cells (treated with 30 ng/ml IL-6 for 2 hrs in 2% serum) followed by 1 μg/ul poly(dI-dC) • poly(dI-dC) (Amersham Biosciences, Piscataway, NJ) and 0.1 pmol 5′HEX-labeled double-stranded oligonucleotide DNA (Midland Certified Reagent Company, Midland, TX) containing the STAT3 direct repeat consensus sequence (5′-GAT CCT TCT GGG ATG ATC TAG ATC-3′) for 15 min. [49] For the experiment of APE1/STAT3 interaction, purified APE1 protein was reduced with 2 mM DTT for 10 min and incubated with a final concentration of 4 μg with 0.4 mM DTT in PBS. Reduced APE1 was added to 15 μg nuclear extract as above. The final concentration of DTT in redox reactions was 0.04 mM. For EMSA with E3330 treatment on nuclear extracts, E3330 was pre-incubated with purified, reduced APE1 in EMSA reaction buffer for 30 min, followed by addition of 3 μg nuclear extract.

Apoptosis and Caspase 3 Activation Assays
Apoptosis was assayed 24 h after inhibitor treatment in the conditions indicated, using Annexin-V-7-AAD [4,50] by flow cytometry. Activation of Caspase 3 was assessed using the FITC-conjugated DEVD-FMK inhibitor in permeabilized PDAC cells, by flow cytometry.

Stable Cell Lines for Reporter Assays
Lenti viral transcripational reporter vectors pGreenFire-STAT3 and the control pGreenFire-mCMV, (System Biosciences Inc., Mountainview, CA) were used to transduce Panc-1 cells, as previously reported. [4] For overexpression experiments, colonies were cotransfected with control pcDNA vector, pcDNA-wtAPE1 or pcDNA-C65A-APE1 and Renilla luciferase vector, pRL-CMV (Promega Corp., Madison, WI), in a 1:10 ratio using Lipofectamine2000. Firefly and Renilla luciferase activities were assayed using the Dual Luciferase Reporter Assay System (Promega Corp., Madison, WI). Transfection experiments were performed in triplicate and repeated at least three times as independent experiments.

For STAT3 transactivation experiments with APE1 siRNA, Panc-1 colonies were transfected with siRNA and assayed for STAT3 activity. With E3330 treatment, cells were treated for 24 h in serum free media and then with IL-6 for 6 h. RLU was normalized to cell viability (MTS assay) as previously described. [4]

Migration Assay
To assay for migration, we utilized xCELLigence DP cell invasion and migration (CIM) system. Cells were serum starved for 18 h and then seeded at 8×10^4 in 80 μl of serum-free medium in the upper chamber with 8 μm pore size while the lower chamber contained media with 10% serum. Cells were pretreated with the inhibitors indicated for 2 h, prior to addition to the well. Cell migration and viability were monitored every hour for 14 h.

Statistics
All data points for vehicle, E3330, STAT3 inhibitor, and combination treatments were analyzed. Statistical analyses were performed using the paired t-test, and for the apoptosis experiments, the one way ANOVA test was used (Sigma Plot software). Differences between groups were considered significant if p<0.05. For the analysis of Combination Index (CI) values using Chou-Talalay method, the CalcuSyn program provided the CI values based on a Dose Effect Analysis. Curves generated using single agent or combination treatment are scored with an r value, the linear correlation coefficient. For these experiments, we required the r value to be above or equal to 0.9. If this requirement is met, CI values are generated which are quantitative measures of the degree of drug interaction based on enzyme kinetic models.

Supporting Information
Figure S1 STAT3 activity is inhibited by APE1 knockdown, however STAT3 mRNA and protein levels do not change. Representative experiment of Panc-1 cells transduced with pGF-STAT3-Luc clones #3 (A) and #9 (B) following transfection with scrambled or APE1 siRNA (50 nM) and induced with IL-6 (50 ng/ml, 6 hr). C) Quantitation of Western blot of total STAT3 protein levels after APE1/Ref-1 knockdown in PaCa-2 cells. Total STAT3 levels were normalized to Tubulin. D) The amount of mRNA for STAT3 was analyzed by qPCR, using RPLP0 as the internal control for patient-derived lines (black bars) and Actin mRNA as the internal control for PaCa-2 (gray bars). For the patient-derived lines, the mRNA from three specimens was measured separately, in triplicate, and then averaged. PaCa-2 was done in three separate experiments in triplicate and the data averaged. E) Quantitation of Western blot for p-STAT3 levels following APE1 knockdown in PaCa-2 cells. p-STAT3 levels were
Renilla activities were assayed using normalized to total STAT3. Data represent average normalized to DMSO, and mean ± SD and are shown. Student’s t tests were performed; *p < 0.05, comparing E3330 versus DMSO. D) Expression of STAT3 target gene, survivin goes down following E3330 treatment (24 h) in PaCa-2 cells (n = 3, avg ± SD) via qPCR.

Figure S5 Combination of STAT3 and APE1 inhibitors inhibit PDAC cell migration. A) Panc-1 cells were serum-starved overnight. Cells (6 x 10⁵) were plated in duplicate in the upper chamber CIM plates with or without FN coating. Cells were also plated in the presence and absence of FBS in the lower chamber. Readings were taken for 12 h following plating. To demonstrate that the cells plated for migration shown in Figure 7 were indeed viable and that the migration of live cells was being monitored, we tested concurrent E-plate assays (B) using the xCELLigence system or MTS assays (C). Cont = DMSO, E = E3330, S3I = S3I-201, ST = STATTIIC. D) Treatment with E3330 (75 µM) with STAT3 inhibitor S3I-201 (100 µM), dramatically reduces the cells’ migratory ability. Quantitation of three individual experiments at 8 hr is shown in F and G. ** p<0.01 using paired t test comparing S3I-201 alone with combination treatment.

Table S1 Dual targeting of thioredoxin and STAT3 is not synergistic in PDAC cells. ED₅₀, −50, and −3₅₀−₈ were determined using the MTS assay.

Author Contributions
Conceived and designed the experiments: AAC MRK MLF. Performed the experiments: YJ ML AMR YH SS MLF. Analyzed the data: AAC YJ ML AMR YH MLF. Contributed reagents/materials/analysis tools: AAC MRK MLF. Wrote the paper: AAC AM MRK MLF.
a gemcitabine-containing combination. Cancer Chemother Pharmacol 67: 503–509.
30. Simon AR, Rai U, Fanburg BL, Cochran BH (1998) Activation of the JAK-STAT pathway by reactive oxygen species. An J Physiol 275: C1640–1652.
31. Ferbeyre G, Moregli R (2011) The role of Stat3 transcription factors as tumor suppressors or oncogenes. Biochim Biophys Acta 1815: 104–114.
32. Kramer OH, Heinzel T (2010) Phosphorylation-acetylation switch in the regulation of STAT1 signaling. Mol Cell Endocrinol 315: 40–46.
33. Turkson J (2004) STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 8: 499–422.
34. Grivennikov SI, Karin M (2010) Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21: 11–19.
35. Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, et al. (2002) Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 123: 2052–2063.
36. Singh-Gupta V, Zhang H, Banerjee S, Kong D, Raibool JJ, et al. (2009) Radiation-induced HIF-1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells. Int J Cancer 124: 1675–1684.
37. Redell MS, Twedtardy DJ (2005) Targeting transcription factors for cancer therapy. Curr Pharm Des 11: 2873–2887.
38. Astsaturov I, Ratushny V, Sukhanova A, Linarson MB, Bagayuki T, et al. (2010) Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies. Sci Signal 3: ra67.
39. Carro MS, Lim WK, Alvarez MJ, Bollu RJ, Zhao X, et al. (2010) The transcriptional network for mesenchymal transformation of brain tumours. Nature 463: 318–325.
40. Liby KT, Royce DB, Raieisong R, Williams CR, Maitra A, et al. (2010) Synthetic tripterepoidos prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prev Res (Phila) 3: 1427–1434.
41. Jaganathan S, Yue P, Turkson J (2010) Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src. J Pharmacol Exp Ther 333: 373–381.
42. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801–1806.
43. Fishel ML, Colvin ES, Luo M, Kelley MR, Robertson KA (2010) Inhibition of the Redox Function of APE1/Ref-1 in Myeloid Leukemia Cell Lines Results in a Hypersensitive Response to Retinoic Acid-induced Differentiation and Apoptosis. Exp Hematol 38: 1178–1188.
44. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27–55.
45. Wang D, Luo M, Kelley MR (2004) Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther 3: 679–686.
46. Fan Z, Beresford PJ, Zhang D, Xu Z, Novina CD, et al. (2003) Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granulocyte A. Nat Immunol 4: 145–153.
47. Jackson MW, Patle LE, Larkoch GA, Donner DB, Stark GR, et al. (2006) Hdm2 nuclear export, regulated by insulin-like growth factor-1/ MAPK/p90Rsk signaling, mediates the transformation of human cells. J Biol Chem 281: 16814–16820.
48. Georgiadis MM, Luo M, Gaur RK, Delaplane S, Li X, et al. (2006) Evolution of the redox function in mammalian apurinic/apyrimidinic endonuclease. Mutat Res 643: 54–63.
49. Preston IR, Tang G, Tilan J, Hill NS, Suzuki Y (2005) Retinooids and pulmonary hypertension. Circulation 111: 782–790.
50. Rabik CA, Fishel ML, Holleran JL, Kasza K, Kelley MR, et al. (2008) Enhancement of cisplatin (cis-diammine dichloroplatinum [II]) cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress. J Pharmacol Exp Ther 327: 442–452.

PLOS ONE | www.plosone.org 13 October 2012 | Volume 7 | Issue 10 | e47462